Related Experiment Video
Updated: Feb 18, 2026
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
Ethyl lucidenates A reverses P-glycoprotein mediated vincristine resistance in K562/A02 cells
Peng Li1, Shi-Yu Chen1, Shao-Xin Shen1
1a Fujian Provincial Key Laboratory of Pharmacology of Natural Medicine, School of Pharmacy , Fujian Medical University , Fuzhou , China.
Abstract:
Multidrug resistance is a major unresolved obstacle to successful cancer chemotherapy. It is often associated with an elevated efflux of a variety of anticancer drugs by ATP-binding cassette transporters including P-glycoprotein, BCRP and MRP1. In this study, the reversal effect of Ethyl lucidenates A on K562/A02 cells was investigated. At concentrations of 10 μM, Ethyl lucidenates A could reverse the resistance of K562/A02 to vincristine up to 7.59 folds. Mechanistically, Ethyl lucidenates A could increase the intracellular accumulation of vincristine in K562/A02 cells through inhibiting the P-glycoprotein mediated drug-transport activity by rhodamine accumulation assay and cell cycle analysis. Further mechanistic investigation found that Ethyl lucidenates A did not alter P-glycoprotein expression. In conclusion, Ethyl lucidenates A could reverse the multidrug resistance of K562/A02 cells via its influence on P-glycoprotein drug-transport activity and thus, be a potential multidrug resistance reversal agent.
Insights
Ethyl lucidenates A reverses multidrug resistance in K562/A02 cancer cells by inhibiting P-glycoprotein activity. This compound enhances vincristine accumulation, showing potential as a multidrug resistance reversal agent.
Area of Science:
- Pharmacology
- Cancer Biology
- Medicinal Chemistry
Background:
- Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy.
- Elevated drug efflux mediated by ATP-binding cassette transporters like P-glycoprotein contributes to MDR.
- Identifying novel MDR reversal agents is crucial for improving treatment efficacy.
Purpose of the Study:
- To investigate the potential of Ethyl lucidenates A as a multidrug resistance reversal agent.
- To elucidate the mechanism by which Ethyl lucidenates A affects drug resistance in K562/A02 cells.
Main Methods:
- K562/A02 cells were treated with Ethyl lucidenates A and vincristine.
- Rhodamine accumulation assay was used to assess P-glycoprotein activity.
- Cell cycle analysis was performed to evaluate drug effects.
Main Results:
- Ethyl lucidenates A reversed vincristine resistance in K562/A02 cells up to 7.59-fold at 10 μM.
- Ethyl lucidenates A increased intracellular vincristine accumulation by inhibiting P-glycoprotein-mediated drug transport.
- Ethyl lucidenates A did not affect P-glycoprotein expression levels.
Conclusions:
- Ethyl lucidenates A demonstrates efficacy in reversing multidrug resistance in K562/A02 cells.
- The mechanism involves modulating P-glycoprotein drug-transport activity, not expression.
- Ethyl lucidenates A represents a promising candidate for a multidrug resistance reversal agent in cancer therapy.
More Related Videos
08:24Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS
Published on: January 23, 2026
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
